-
Je něco špatně v tomto záznamu ?
The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors
T. Otava, M. Šála, F. Li, J. Fanfrlík, K. Devkota, S. Perveen, I. Chau, P. Pakarian, P. Hobza, M. Vedadi, E. Boura, R. Nencka
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
Wellcome Trust - United Kingdom
- MeSH
- COVID-19 * MeSH
- exoribonukleasy MeSH
- lidé MeSH
- ligandy MeSH
- methyltransferasy * genetika MeSH
- SARS-CoV-2 MeSH
- virové nestrukturální proteiny MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In this study, we have focused on the structure-based design of the inhibitors of one of the two SARS-CoV-2 methyltransferases (MTases), nsp14. This MTase catalyzes the transfer of the methyl group from S-adenosyl-l-methionine (SAM) to cap the guanosine triphosphate moiety of the newly synthesized viral RNA, yielding the methylated capped RNA and S-adenosyl-l-homocysteine (SAH). As the crystal structure of SARS-CoV-2 nsp14 is unknown, we have taken advantage of its high homology to SARS-CoV nsp14 and prepared its homology model, which has allowed us to identify novel SAH derivatives modified at the adenine nucleobase as inhibitors of this important viral target. We have synthesized and tested the designed compounds in vitro and shown that these derivatives exert unprecedented inhibitory activity against this crucial enzyme. The docking studies nicely explain the contribution of an aromatic part attached by a linker to the position 7 of the 7-deaza analogues of SAH.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025122
- 003
- CZ-PrNML
- 005
- 20211026134112.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acsinfecdis.1c00131 $2 doi
- 035 __
- $a (PubMed)34152728
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Otava, Tomáš $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic $u Faculty of Food and Biochemical Technology, University of Chemistry and Technology, 166 28, Prague 6, Czech Republic
- 245 14
- $a The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors / $c T. Otava, M. Šála, F. Li, J. Fanfrlík, K. Devkota, S. Perveen, I. Chau, P. Pakarian, P. Hobza, M. Vedadi, E. Boura, R. Nencka
- 520 9_
- $a In this study, we have focused on the structure-based design of the inhibitors of one of the two SARS-CoV-2 methyltransferases (MTases), nsp14. This MTase catalyzes the transfer of the methyl group from S-adenosyl-l-methionine (SAM) to cap the guanosine triphosphate moiety of the newly synthesized viral RNA, yielding the methylated capped RNA and S-adenosyl-l-homocysteine (SAH). As the crystal structure of SARS-CoV-2 nsp14 is unknown, we have taken advantage of its high homology to SARS-CoV nsp14 and prepared its homology model, which has allowed us to identify novel SAH derivatives modified at the adenine nucleobase as inhibitors of this important viral target. We have synthesized and tested the designed compounds in vitro and shown that these derivatives exert unprecedented inhibitory activity against this crucial enzyme. The docking studies nicely explain the contribution of an aromatic part attached by a linker to the position 7 of the 7-deaza analogues of SAH.
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a exoribonukleasy $7 D005095
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 12
- $a methyltransferasy $x genetika $7 D008780
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a virové nestrukturální proteiny $7 D017361
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šála, Michal $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic
- 700 1_
- $a Li, Fengling
- 700 1_
- $a Fanfrlík, Jindřich $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic
- 700 1_
- $a Devkota, Kanchan
- 700 1_
- $a Perveen, Sumera
- 700 1_
- $a Chau, Irene
- 700 1_
- $a Pakarian, Paknoosh
- 700 1_
- $a Hobza, Pavel $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic
- 700 1_
- $a Vedadi, Masoud
- 700 1_
- $a Boura, Evzen $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic
- 700 1_
- $a Nencka, Radim $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, v.v.i., Gilead Sciences Research Centre at the IOCB Prague, Flemingovo nam. 2., 166 10 Prague 6, Czech Republic
- 773 0_
- $w MED00205751 $t ACS infectious diseases $x 2373-8227 $g Roč. 7, č. 8 (2021), s. 2214-2220
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34152728 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134118 $b ABA008
- 999 __
- $a ok $b bmc $g 1714257 $s 1145629
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 7 $c 8 $d 2214-2220 $e 20210621 $i 2373-8227 $m ACS infectious diseases $n ACS infect. dis. $x MED00205751
- GRA __
- $p Wellcome Trust $2 United Kingdom
- LZP __
- $a Pubmed-20211013